Quick Facts
Plain-English Summary
Melanotan I — now known generically as afamelanotide — is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring tridecapeptide produced in the pituitary and skin. The analogue was developed in the 1980s at the University of Arizona by Victor Hruby and Mac Hadley, who introduced two amino acid substitutions relative to native α-MSH: norleucine at position 4 (replacing methionine) and D-phenylalanine at position 7 (replacing L-phenylalanine). These changes markedly increase both receptor binding affinity and resistance to enzymatic degradation, giving the compound a longer effective window and stronger melanogenic signal than the natural peptide.
Afamelanotide acts primarily through the melanocortin-1 receptor (MC1R), which is expressed on melanocytes in the skin. Activation of MC1R stimulates the production of eumelanin — the dark, photoprotective form of melanin — in a process called melanogenesis. This provides the basis for its therapeutic rationale: by increasing constitutive eumelanin levels, the compound can extend the window of pain-free light exposure in patients with conditions where skin photosensitivity is severe and disabling.
The primary approved indication is erythropoietic protoporphyria (EPP), a rare inherited disorder caused by mutations in ferrochelatase that lead to accumulation of protoporphyrin IX. In EPP, even brief sun exposure causes severe, immediate pain and sometimes tissue damage — a debilitating condition with no previously effective treatment. Clinuvel Pharmaceuticals pursued and obtained EMA approval (2014) and FDA approval (2019) for Scenesse, a 16 mg biodegradable subcutaneous implant that releases afamelanotide slowly over approximately 60 days.
Approved for EPP, not cosmetic tanning. The Scenesse approval covers a specific rare disease (EPP) where melanin induction provides a clinically meaningful reduction in photosensitivity pain. The FDA and EMA approvals do not extend to skin tanning for cosmetic purposes, sun protection in the general population, or any other indication. Off-label compounded MT-I use for tanning is not supported by this regulatory history.
Melanotan I is importantly distinct from Melanotan II. MT-II is a cyclic heptapeptide that is non-selective across melanocortin receptors, hitting MC1R, MC3R, and MC4R. MC4R activation drives the well-documented side effects of MT-II: spontaneous erections, libido changes, and nausea. MT-I does not carry these effects in clinical use — its selectivity for MC1R means it produces melanogenesis without meaningful MC4R engagement. This receptor profile distinction is clinically significant and should not be conflated by users comparing the two compounds.
Beyond EPP, afamelanotide has been studied in Phase II trials for other photodermatoses including vitiligo, polymorphic light eruption (PLE), and solar urticaria. Results have been variable, and no additional indications have progressed to Phase III or received regulatory approval as of 2026.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| Guinea pig UV photoprotection | Afamelanotide pre-treatment significantly increased constitutive melanin and reduced UV-induced erythema. Established pharmacodynamic basis for human trials. Hadley ME et al. 1991 ↗ | Preclinical |
| Rodent melanogenesis dose-response | Clear dose-dependent increase in skin melanin content following SC afamelanotide. D-Phe7 substitution confirmed to extend half-life vs. native α-MSH, supporting implant delivery rationale. | Preclinical |
| MC1R receptor binding (in vitro) | Afamelanotide demonstrates 10–100× higher MC1R binding affinity than native α-MSH. Selectivity profiling confirms minimal activity at MC3R and MC4R at concentrations reached with the approved 16 mg implant. Hruby VJ et al. 1999 ↗ | Preclinical |
| Rodent inflammation models | Some data suggest anti-inflammatory effects via MC1R-mediated pathways; however, this body of work is considerably thinner than for BPC-157 or TB-500, and human relevance is not established for these secondary indications. | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| Phase III — EPP (EU) | 74 adult EPP patients; afamelanotide 16 mg SC implant vs. placebo; double-blind RCT | — | Phase III · Published |
| Phase III — EPP (US) | 94 adult EPP patients; afamelanotide 16 mg SC implant vs. placebo; double-blind RCT | — | Phase III · FDA Basis |
| Phase II — Vitiligo | ~55 patients; NB-UVB plus afamelanotide implant vs. NB-UVB alone | — | Phase II |
| Phase II — Polymorphic Light Eruption (PLE) | Small cohort; afamelanotide pre-treatment before controlled UV challenge | — | Phase II |
| Phase II — Solar Urticaria | Small open-label study; afamelanotide implant, 6–12 month follow-up | — | Phase II · Open Label |
| Cosmetic tanning use | Off-label compounded SC injection; no controlled trial registered | — | No Trial Data |
Melanotan I has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
Safety data from Phase III EPP trials is more robust than for most research peptides. Common adverse events in trials were transient nausea (most common, dose-related, generally resolving within 24 hours post-implant), implantation site reactions, fatigue, and headache. No serious cardiac, renal, or hepatic adverse events were attributed to the drug in Phase III. Approved with an acceptable risk-benefit profile for EPP by both FDA and EMA.
Regulatory agencies have required post-marketing monitoring for effects on melanocytic nevi (moles). Systematic stimulation of melanogenesis raises a theoretical question about potential nevi growth or melanoma risk with prolonged use. No clinical evidence of increased melanoma incidence has been identified in EPP trial populations, but the patient numbers and follow-up duration are insufficient to rule out a small absolute risk increase. Long-term cosmetic use is entirely unstudied.
- Nausea, flushing, and facial tingling post-injection
- Unwanted hyperpigmentation of moles and freckles
- Darkening of existing skin lesions — warrants dermatologic review
- Mild erection (less frequent than MT-II due to MC1R selectivity)
- Spontaneous stretching or yawning (reported with MT-II; uncommon with MT-I)
- No pharmacovigilance database exists for compounded MT-I
- Personal or family history of melanoma or dysplastic nevi
- Pregnancy or breastfeeding (no safety data)
- Active autoimmune skin conditions
- Concurrent immunosuppressive therapy
- Children and adolescents
- Use of unregulated compounded product without medical supervision
Melanotan I is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of Melanotan I for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
The MT-I vs MT-II distinction is genuinely important and gets collapsed constantly in this community. MT-I is MC1R selective — you get melanogenesis and that's largely it. MT-II hits MC4R too, which is why you get the erections and the appetite suppression and the spontaneous stretching. Different compound, different receptor profile, different risk calculus. Someone comparing their MT-II protocol to MT-I as if they're interchangeable is working from incorrect premises. The FDA approval of afamelanotide for EPP is specifically tied to this selectivity — it's not a coincidence that the non-selective one didn't make it through Phase III for any indication.
Correct. And the dosing is completely different too. The approved Scenesse implant is 16 mg delivered over ~60 days — a controlled, slow-release format. People injecting compounded MT-I at high acute doses are delivering the same total compound in a pharmacokinetic profile that was never studied in Phase III. You don't get to borrow the regulatory credibility of Scenesse and apply it to a different delivery system.
For what it's worth from the EPP side: the Harms NEJM trial was a meaningful result for a disease that had essentially no effective treatment. The median increase in pain-free sun exposure was real and clinically significant for that population — EPP pain is severe and immediate, not a minor inconvenience. Afamelanotide doesn't cure EPP, doesn't eliminate all photosensitivity, and is still not reimbursed in many countries due to cost. But treating this as primarily a tanning compound misrepresents what the clinical program was actually solving for.
The nevi monitoring requirement from regulators is not a formality. Systematically stimulating melanogenesis across the whole body, repeatedly, for cosmetic purposes in people without EPP is a different risk profile than treating a disease where the alternative is a life severely restricted by photosensitivity. The trial populations had EPP — a specific genetic condition where this trade-off was clearly favourable. Extrapolating that risk-benefit calculation to healthy individuals using compounded MT-I for a tan is not a reasonable inference from the available evidence.
Agreed. The compound is genuinely well-characterised at the receptor and mechanistic level — the science is solid. The problem is the disconnect between "this drug works for EPP under controlled conditions" and "this means it's safe for anyone to inject to get a tan." Those are not the same statement.
MT-I is honestly one of the more interesting compounds in this space from an evidence standpoint — it's the rare peptide with published Phase III data and a legitimate regulatory approval. The Harms NEJM paper is solid work. What I find worth flagging is that the vitiligo and PLE Phase II data is weaker than people realise. The repigmentation effect in vitiligo required NB-UVB combination therapy; MT-I alone wasn't sufficient. And the PLE data is very small-sample preliminary. The EPP indication is well-supported; everything else is still speculative.